Abstract
A clinical development program between the American and European arms of a multinational pharmaceutical company can be integrated, shared, or separate. The first two options allow faster development and may facilitate earlier marketing. The basic requirements are an agreed policy across the Atlantic on respective contributions to the corporate clinical trial program, then the harmonization of trial design, data capture, and analysis.
Get full access to this article
View all access options for this article.